- Home
- BRLT vs CCEL Comparison
BRLT vs CCEL Comparison
Compare BRLT & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | CCEL |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 35.8M |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | BRLT | CCEL |
|---|---|---|
| Price | $1.73 | $3.57 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $1.80 | N/A |
| AVG Volume (30 Days) | ★ 116.2K | 3.6K |
| Earning Date | 11-05-2025 | 10-15-2025 |
| Dividend Yield | N/A | ★ 11.17% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $432,597,000.00 | $31,747,500.00 |
| Revenue This Year | $5.48 | $0.30 |
| Revenue Next Year | $3.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $1.25 | $3.58 |
| 52 Week High | $3.10 | $8.86 |
Technical Indicators
Market Signals| Indicator | BRLT | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 34.76 |
| Support Level | $1.63 | $4.04 |
| Resistance Level | $1.93 | $4.45 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 15.94 | 6.85 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.